$KPTI News

Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript

Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted For Late-Breaking Oral Presentation At EHA 2026

Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentation Titled: Selinexor Plus Ruxolitinib In JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial At 2026 ASCO Annual Meeting

Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Posts Q1 Beat and Highlights ASCO Presentation, Shares Surge 7%

Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript

Karyopharm Therapeutics Inc. 2026 Q1 - Results - Earnings Call Presentation

Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $137.489M Est

Karyopharm Therapeutics Q1 EPS $(1.24) Beats $(1.40) Estimate, Sales $35.066M Beat $31.399M Estimate

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $13

Karyopharm Therapeutics Files Prospectus For Offering $400M Mixed Shelf

Karyopharm Therapeutics Phase 3 SENTRY Trial In Myelofibrosis Accepted For Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Piper Sandler Reiterates Overweight on Karyopharm Therapeutics, Lowers Price Target to $8

Karyopharm: Putting The Phase 3 Trial In Context

Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $15

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis - Slideshow

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

Karyopharm Therapeutics shares are trading lower after the company reported mixed results from its Phase 3 SENTRY trial for myelofibrosis.

Karyopharm Therapeutics shares are trading lower after the company reported mixed results from its Phase 3 SENTRY trial for myelofibrosis.